Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

  • Walo-Delgado, Paulette Esperanza
  • Medina, Silvia
  • Quintana, Ester
  • Fernández-Velasco, José Ignacio
  • Montalban Gairín, Xavier
  • Midaglia Fernandez, Luciana
  • Sainz de la Maza, Susana
  • Comabella Lopez, Manuel
  • Monreal, Enric
Células B; Alemtuzumab; Autoinmunidad, Limfòcits B; Alemtuzumab; Autoimmunitat, B cells; Alemtuzumab; Autoimmunity, Objective: To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Methods: Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Results: Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). Conclusions: A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.​, This work was supported by grants from Red Española de Esclerosis Múltiple (REEM) (RD16/0015/0001; RD16/0015/0004; RD16/0015/0006; RD16/0015/0013) and PI18/00572 integrated in the Plan Estatal I+D+I and co-funded by ISCIII-Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS

  • Matute Blanch, Clara
  • Osman, Mohamoud
  • Costa Riu, Carme
  • Pinteac, Rucsanda
  • Miró Cau, Berta
  • Sánchez Pla, Alex
  • Brito, Veronica Ines
  • Montalban Gairín, Xavier
  • Comabella Lopez, Manuel
  • Fissolo, Nicolás Miguel
Multiple sclerosis; SERPINA3, Esclerosi múltiple; SERPINA3, Esclerosis múltiple; SERPINA3, Objective To identify biomarkers associated with progressive phases of MS and with neuroprotective potential. Methods Combined analysis of the transcriptional and proteomic profiles obtained in CNS tissue during chronic progressive phases of experimental autoimmune encephalomyelitis (EAE) with the transcriptional profile obtained during the differentiation of murine neural stem cells into neurons. Candidate biomarkers were measured by ELISA in the CSF of 65 patients with MS (29 with relapsing-remitting MS [RRMS], 20 with secondary progressive MS, and 16 with primary progressive MS [PPMS]) and 30 noninflammatory neurologic controls (NINCs). Results Integrative analysis of gene and protein expression data identified 2 biomarkers, the serine protease inhibitor Serpina3n and the calcium-binding protein S100A4, which were upregulated in chronic progressive EAE and whose expression was induced during neuronal differentiation. Immunofluorescence studies revealed a primarily neuronal expression of S100A4 and Serpina3n during EAE. CSF levels of SERPINA3, the human ortholog of murine Serpina3n, and S100A4 were increased in patients with MS compared with NINCs (SERPINA3: 1,320 vs 838.6 ng/mL, p = 0.0001; S100A4: 1.6 vs 0.8 ng/mL, p = 0.02). Within the MS group, CSF SERPINA3 levels were significantly elevated in patients with progressive forms, mainly patients with PPMS compared with patients with RRMS (1,617 vs 1,129 ng/mL, p = 0.02) and NINCs (1,617 vs 838.6 ng/mL, p = 0.0001). Of interest, CSF SERPINA3 levels significantly correlated with CSF neurofilament light chain levels only in the PPMS group (r = 0.62, p = 0.01). Conclusion These results point to a role of SERPINA3 as a biomarker associated with the progressive forms of MS, particularly PPMS., This work was supported by grants from the Fondo de Investigación Sanitaria (FIS; grant number PI17/00596), Ministry of Science and Innovation, Spain; Generalitat de Catalunya Suport Grups de Recerca (2017 SGR 0527); and the Red Española de Esclerosis Múltiple (RD16/0015/0004) funded by the FIS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

  • Gil Varea, Elia|||0000-0001-5144-4144
  • Urcelay, Elena|||0000-0001-8470-8396
  • Vilariño-Güell, Carles|||0000-0002-5612-5940
  • Costa, Carme|||0000-0001-9577-3839
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Matesanz, Fuencisla|||0000-0002-9429-1819
  • Rodríguez Antigüedad, Alfredo|||0000-0001-5975-725X
  • Oksenberg, Jorge
  • Espino-Paisan, Laura
  • Dessa Sadovnick, A.
  • Saiz, Albert|||0000-0002-5793-8791
  • Villar, Luisa M.|||0000-0002-9067-3668
  • García Merino, Juan Antonio
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Triviño, Juan Carlos
  • Quintana, Ester|||0000-0001-8885-1931
  • Robles, René
  • Sánchez López, Antonio José|||0000-0001-7168-6175
  • Arroyo, Rafael
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Malhotra, Sunny|||0000-0003-1112-7739
  • Fissolo, Nicolás|||0000-0002-7701-9346
  • Montalban, Xavier|||0000-0002-0098-9918
  • Comabella López, Manuel|||0000-0002-2373-6657
It remains unclear whether disease course in multiple sclerosis (MS) is influenced by genetic polymorphisms. Here, we aimed to identify genetic variants associated with benign and aggressive disease courses in MS patients. MS patients were classified into benign and aggressive phenotypes according to clinical criteria. We performed exome sequencing in a discovery cohort, which included 20 MS patients, 10 with benign and 10 with aggressive disease course, and genotyping in 2 independent validation cohorts. The first validation cohort encompassed 194 MS patients, 107 with benign and 87 with aggressive phenotypes. The second validation cohort comprised 257 patients, of whom 224 patients had benign phenotypes and 33 aggressive disease courses. Brain immunohistochemistries were performed using disease course associated genes antibodies. By means of single-nucleotide polymorphism (SNP) detection and comparison of allele frequencies between patients with benign and aggressive phenotypes, a total of 16 SNPs were selected for validation from the exome sequencing data in the discovery cohort. Meta-analysis of genotyping results in two validation cohorts revealed two polymorphisms, rs28469012 and rs10894768, significantly associated with disease course. SNP rs28469012 is located in CPXM2 (carboxypeptidase X, M14 family, member 2) and was associated with aggressive disease course (uncorrected p value < 0.05). SNP rs10894768, which is positioned in IGSF9B (immunoglobulin superfamily member 9B) was associated with benign phenotype (uncorrected p value < 0.05). In addition, a trend for association with benign phenotype was observed for a third SNP, rs10423927, in NLRP9 (NLR family pyrin domain containing 9). Brain immunohistochemistries in chronic active lesions from MS patients revealed expression of IGSF9B in astrocytes and macrophages/microglial cells, and expression of CPXM2 and NLRP9 restricted to brain macrophages/microglia. Genetic variants located in CPXM2, IGSF9B, and NLRP9 have the potential to modulate disease course in MS patients and may be used as disease activity biomarkers to identify patients with divergent disease courses. Altogether, the reported results from this study support the influence of genetic factors in MS disease course and may help to better understand the complex molecular mechanisms underlying disease pathogenesis. The online version of this article (10.1186/s12974-018-1307-1) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS

  • Fissolo, Nicolás|||0000-0002-7701-9346
  • Matute-Blanch, Clara|||0000-0002-1779-0008
  • Osman, Mohamoud
  • Costa, Carme|||0000-0001-9577-3839
  • Pinteac, Rucsanda|||0000-0001-5215-3912
  • Miró, Berta|||0000-0001-6049-8697
  • Sánchez, Alex|||0000-0002-8673-7737
  • Brito, Verónica|||0000-0002-4137-0708
  • Dujmovic, Irena|||0000-0002-5179-1901
  • Voortman, Margarete|||0000-0001-7357-2868
  • Khalil, Michael|||0000-0002-5350-3328
  • Borràs, Eva|||0000-0002-3859-9907
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Issazadeh-Navikas, Shohreh|||0000-0003-0369-424X
  • Montalban, Xavier|||0000-0002-0098-9918
  • Comabella López, Manuel|||0000-0002-2373-6657
To identify biomarkers associated with progressive phases of MS and with neuroprotective potential. Combined analysis of the transcriptional and proteomic profiles obtained in CNS tissue during chronic progressive phases of experimental autoimmune encephalomyelitis (EAE) with the transcriptional profile obtained during the differentiation of murine neural stem cells into neurons. Candidate biomarkers were measured by ELISA in the CSF of 65 patients with MS (29 with relapsing-remitting MS [RRMS], 20 with secondary progressive MS, and 16 with primary progressive MS [PPMS]) and 30 noninflammatory neurologic controls (NINCs). Integrative analysis of gene and protein expression data identified 2 biomarkers, the serine protease inhibitor Serpina3n and the calcium-binding protein S100A4, which were upregulated in chronic progressive EAE and whose expression was induced during neuronal differentiation. Immunofluorescence studies revealed a primarily neuronal expression of S100A4 and Serpina3n during EAE. CSF levels of SERPINA3, the human ortholog of murine Serpina3n, and S100A4 were increased in patients with MS compared with NINCs (SERPINA3: 1,320 vs 838.6 ng/mL, p = 0.0001; S100A4: 1.6 vs 0.8 ng/mL, p = 0.02). Within the MS group, CSF SERPINA3 levels were significantly elevated in patients with progressive forms, mainly patients with PPMS compared with patients with RRMS (1,617 vs 1,129 ng/mL, p = 0.02) and NINCs (1,617 vs 838.6 ng/mL, p = 0.0001). Of interest, CSF SERPINA3 levels significantly correlated with CSF neurofilament light chain levels only in the PPMS group (r = 0.62, p = 0.01). These results point to a role of SERPINA3 as a biomarker associated with the progressive forms of MS, particularly PPMS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells

  • Gil Varea, Elia|||0000-0001-5144-4144
  • Fedetz, Maria
  • Eixarch, Herena|||0000-0001-7525-9533
  • Spataro, Nino|||0000-0002-2127-2238
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Urcelay, Elena|||0000-0001-8470-8396
  • Saiz, Albert|||0000-0002-5793-8791
  • Fernández Fernández, Óscar|||0000-0003-3696-789X
  • Leyva, Laura|||0000-0003-0620-9625
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Vandenbroeck, Koen|||0000-0002-6967-6485
  • Otaegui, David|||0000-0002-6625-5976
  • Castillo-Triviño, Tamara|||0000-0002-9249-3185
  • Izquierdo, Guillermo|||0000-0002-6340-5609
  • Malhotra, Sunny|||0000-0003-1112-7739
  • Bosch, Elena|||0000-0003-2848-103X
  • Navarro, Arcadi|||0000-0003-2162-8246
  • Alcina, Antonio|||0000-0001-7294-0948
  • Montalban, Xavier|||0000-0002-0098-9918
  • Matesanz, Fuencisla|||0000-0002-9429-1819
  • Comabella López, Manuel|||0000-0002-2373-6657
Genome-wide association studies and meta-analysis have contributed to the identification of more than 200 loci associated with multiple sclerosis (MS). However, a proportion of MS heritability remains unknown. We aimed to uncover new genetic variants associated with MS and determine their functional effects. For this, we resequenced the exons and regulatory sequences of 14 MS risk genes in a cohort of MS patients and healthy individuals (n = 1070) and attempted to validate a selection of signals through genotyping in an independent cohort (n = 5138). We identified three new MS-associated variants at C-X-C motif chemokine receptor 5 (CXCR5), Ts translation elongation factor, mitochondrial (TSFM) and cytochrome P450 family 24 subfamily A member 1 (CYP24A1). Rs10892307 resulted in a new signal at the CXCR5 region that explains one of the associations with MS within the locus. This polymorphism and three others in high linkage disequilibrium mapped within regulatory regions. Of them, rs11602393 showed allele-dependent enhancer activity in the forward orientation as determined by luciferase reporter assays. Immunophenotyping using peripheral blood mononuclear cells from MS patients associated the minor allele of rs10892307 with increased percentage of regulatory T cells expressing CXCR5. This work reports a new signal for the CXCR5 MS risk locus and points to rs11602393 as the causal variant. The expansion of CXCR5+ circulating regulatory T cells induced by this variant could cause its MS association.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus

  • Carrillo-Salinas, Francisco J.|||0000-0002-7936-5859
  • Mestre, Leyre|||0000-0001-6970-2316
  • Mecha, Miriam
  • Feliú, Ana|||0000-0002-1157-1525
  • del Campo, Rosa|||0000-0003-1147-7923
  • Villarrubia, Noelia
  • Espejo, Carmen|||0000-0001-9949-5901
  • Montalban, Xavier|||0000-0002-0098-9918
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Villar, L. M.
  • Guaza, Carmen|||0000-0003-3240-9807
Recent studies have begun to point out the contribution of microbiota to multiple sclerosis (MS) pathogenesis. Theiler's murine encephalomyelitis virus induced demyelinating disease (TMEV-IDD) is a model of progressive MS. Here, we first analyze the effect of intracerebral infection with TMEV on commensal microbiota and secondly, whether the early microbiota depletion influences the immune responses to TMEV on the acute phase (14 dpi) and its impact on the chronic phase (85 dpi). The intracranial inoculation of TMEV was associated with a moderate dysbiosis. The oral administration of antibiotics (ABX) of broad spectrum modified neuroimmune responses to TMEV dampening brain CD4 + and CD8 + T infiltration during the acute phase. The expression of cytokines, chemokines and VP2 capsid protein was enhanced and accompanied by clusters of activated microglia disseminated throughout the brain. Furthermore, ABX treated mice displayed lower levels of CD4 + and CD8 + T cells in cervical and mesenteric lymph nodes. Increased mortality to TMEV was observed after ABX cessation at day 28pi. On the chronic phase, mice that survived after ABX withdrawal and recovered microbiota diversity showed subtle changes in brain cell infiltrates, microglia and gene expression of cytokines. Accordingly, the surviving mice of the group ABX-TMEV displayed similar disease severity than TMEV mice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

  • Walo-Delgado, Paulette Esperanza
  • Monreal, Enric|||0000-0003-3293-0125
  • Medina, Silvia|||0000-0002-6051-173X
  • Quintana, Ester|||0000-0001-8885-1931
  • Sainz de la Maza, Susana|||0000-0001-8605-0049
  • Fernández Velasco, José Ignacio|||0000-0001-9148-671X
  • Lapuente, Paloma
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Montalban, Xavier|||0000-0002-0098-9918
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Villarrubia, Noelia
  • Carrasco-Sayalero, Angela
  • Rodríguez-Martín, Eulalia
  • Roldán, Ernesto
  • Meca-Lallana, Jose Eustasio|||0000-0001-5050-9890
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Villar, Luisa M|||0000-0002-9067-3668
UDHEBRON, To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.​
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

  • Walo-Delgado, Paulette Esperanza
  • Medina, Silvia
  • Quintana, Ester
  • Fernández-Velasco, José Ignacio
  • Montalban, Xavier
  • Midaglia Fernandez, Luciana
  • Sainz de la Maza, Susana
  • Comabella Lopez, Manuel
  • Monreal, Enric
Células B; Alemtuzumab; Autoinmunidad, Limfòcits B; Alemtuzumab; Autoimmunitat, B cells; Alemtuzumab; Autoimmunity, Objective: To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Methods: Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Results: Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). Conclusions: A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.​, This work was supported by grants from Red Española de Esclerosis Múltiple (REEM) (RD16/0015/0001; RD16/0015/0004; RD16/0015/0006; RD16/0015/0013) and PI18/00572 integrated in the Plan Estatal I+D+I and co-funded by ISCIII-Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS

  • Matute Blanch, Clara
  • Osman, Mohamoud
  • Costa Riu, Carme
  • Pinteac, Rucsanda
  • Miró Cau, Berta
  • Sánchez Pla, Alex
  • Brito, Veronica Ines
  • Montalban, Xavier
  • Comabella Lopez, Manuel
  • Fissolo, Nicolás Miguel
Multiple sclerosis; SERPINA3, Esclerosi múltiple; SERPINA3, Esclerosis múltiple; SERPINA3, Objective To identify biomarkers associated with progressive phases of MS and with neuroprotective potential. Methods Combined analysis of the transcriptional and proteomic profiles obtained in CNS tissue during chronic progressive phases of experimental autoimmune encephalomyelitis (EAE) with the transcriptional profile obtained during the differentiation of murine neural stem cells into neurons. Candidate biomarkers were measured by ELISA in the CSF of 65 patients with MS (29 with relapsing-remitting MS [RRMS], 20 with secondary progressive MS, and 16 with primary progressive MS [PPMS]) and 30 noninflammatory neurologic controls (NINCs). Results Integrative analysis of gene and protein expression data identified 2 biomarkers, the serine protease inhibitor Serpina3n and the calcium-binding protein S100A4, which were upregulated in chronic progressive EAE and whose expression was induced during neuronal differentiation. Immunofluorescence studies revealed a primarily neuronal expression of S100A4 and Serpina3n during EAE. CSF levels of SERPINA3, the human ortholog of murine Serpina3n, and S100A4 were increased in patients with MS compared with NINCs (SERPINA3: 1,320 vs 838.6 ng/mL, p = 0.0001; S100A4: 1.6 vs 0.8 ng/mL, p = 0.02). Within the MS group, CSF SERPINA3 levels were significantly elevated in patients with progressive forms, mainly patients with PPMS compared with patients with RRMS (1,617 vs 1,129 ng/mL, p = 0.02) and NINCs (1,617 vs 838.6 ng/mL, p = 0.0001). Of interest, CSF SERPINA3 levels significantly correlated with CSF neurofilament light chain levels only in the PPMS group (r = 0.62, p = 0.01). Conclusion These results point to a role of SERPINA3 as a biomarker associated with the progressive forms of MS, particularly PPMS., This work was supported by grants from the Fondo de Investigación Sanitaria (FIS; grant number PI17/00596), Ministry of Science and Innovation, Spain; Generalitat de Catalunya Suport Grups de Recerca (2017 SGR 0527); and the Red Española de Esclerosis Múltiple (RD16/0015/0004) funded by the FIS.